Inventiva S.A. ADR (IVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IVA Stock Summary
- Of note is the ratio of INVENTIVA SA's sales and general administrative expense to its total operating expenses; merely 6.69% of US stocks have a lower such ratio.
- With a price/sales ratio of 19.24, INVENTIVA SA has a higher such ratio than 94.07% of stocks in our set.
- In terms of volatility of its share price, IVA is more volatile than 89.49% of stocks we're observing.
- Stocks that are quantitatively similar to IVA, based on their financial statements, market capitalization, and price volatility, are ARAV, FSR, GOVX, IMMP, and OPT.
- IVA's SEC filings can be seen here. And to visit INVENTIVA SA's official web site, go to www.inventivapharma.com.
IVA Stock Price Chart Interactive Chart >
IVA Price/Volume Stats
| Current price | $4.49 | 52-week high | $14.33 |
| Prev. close | $4.45 | 52-week low | $3.49 |
| Day low | $4.35 | Volume | 362 |
| Day high | $4.49 | Avg. volume | 25,455 |
| 50-day MA | $4.75 | Dividend yield | N/A |
| 200-day MA | $7.22 | Market Cap | 183.52M |
Inventiva S.A. ADR (IVA) Company Bio
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Latest IVA News From Around the Web
Below are the latest news stories about INVENTIVA SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the USNew patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Compa |
Inventiva announces a new Director of the Board of DirectorsDaix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva’s board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of S |
Inventiva reports 2022 Third Quarter Financial Information¹Cash position2 at €72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022Revenues of €0.1m for the first nine months of 2022 Daix (France), Long Island City (New York, United States), November 10, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepat |
Inventiva Down After Development of Cedirogant PausedShares of Inventiva (NASDAQ: IVA) were down in pre-market trading as the clinical-stage biopharmaceutical company announced that AbbVie (ABBV) announced on Friday that it was stopping the development of cedirogant (ABBV- 157), a drug jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases. Frédéric Cren, Chairman, CEO, and Co-Founder of Inventiva commented, "Although we are disappointed to see the end of cedirogant’s clinical program following the analysis of a nonclinical toxicology study, we wish to thank our partner AbbVie for 10 years of collaboration. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back and get ready for another week of trading as we break down the biggest pre-market stock movers for Monday morning! |
IVA Price Returns
| 1-mo | 4.50% |
| 3-mo | 11.97% |
| 6-mo | -49.27% |
| 1-year | -67.11% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -67.13% |
| 2021 | -5.79% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...